To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Stock Exchange Releases
English
Initiator Pharma A/S – Resolutions of the annual general meeting 2023
The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 26 May 2023 at 10.00 AM CEST.
INITIATOR PHARMA: Q1 2023 REPORT
Business highlights in Q1 2023 In March the Company announced the completion of dosing of all 24 patients the the Phase IIa clinical trial with IP2018 and that preliminary results are expected end…
Annual report and Remuneration report 2022 for Initiator Pharma A/S
Initiator Pharma’s Annual Report 2022 and Remuneration Report 2022 has now been published and is available on the company´s home page.
Initiator Pharma: Financial calendar for 2023
Initiator Pharma A/S (“Initiator” or the “Company”) announces that the board of directors expects to publish financial reports according to the following schedule:
Result of incentive program “LTI2022” in Initiator Pharma A/S
The AGM held on May 24, 2022 approved two long-term incentive programs (“LTI2022”), one for Management and leading employees and one for board members.LTI2022 for Management and leading…
Last day of trading in BTA in Initiator Pharma
Initiator Pharma A/S (“Initiator Pharma” or “the Company”) rights issue has now been registered with the Danish Companies Registration Office. The Company hereby announces that the last day of trading in paid subscribed shares (Sw. BTA) will be on 21 July 2022 and stop day will be on 25 July 2022.